BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 31101504)

  • 1. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible.
    Girda E; Huang EC; Leiserowitz GS; Smith LH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1701-1707. PubMed ID: 28683005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
    Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
    Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.
    Boretto M; Maenhoudt N; Luo X; Hennes A; Boeckx B; Bui B; Heremans R; Perneel L; Kobayashi H; Van Zundert I; Brems H; Cox B; Ferrante M; Uji-I H; Koh KP; D'Hooghe T; Vanhie A; Vergote I; Meuleman C; Tomassetti C; Lambrechts D; Vriens J; Timmerman D; Vankelecom H
    Nat Cell Biol; 2019 Aug; 21(8):1041-1051. PubMed ID: 31371824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
    Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
    Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
    Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
    Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
    Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
    Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
    Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
    Sachs N; de Ligt J; Kopper O; Gogola E; Bounova G; Weeber F; Balgobind AV; Wind K; Gracanin A; Begthel H; Korving J; van Boxtel R; Duarte AA; Lelieveld D; van Hoeck A; Ernst RF; Blokzijl F; Nijman IJ; Hoogstraat M; van de Ven M; Egan DA; Zinzalla V; Moll J; Boj SF; Voest EE; Wessels L; van Diest PJ; Rottenberg S; Vries RGJ; Cuppen E; Clevers H
    Cell; 2018 Jan; 172(1-2):373-386.e10. PubMed ID: 29224780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Organoids of Cholangiocarcinoma.
    Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
    Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
    Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
    Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
    Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.
    Choo N; Ramm S; Luu J; Winter JM; Selth LA; Dwyer AR; Frydenberg M; Grummet J; Sandhu S; Hickey TE; Tilley WD; Taylor RA; Risbridger GP; Lawrence MG; Simpson KJ
    SLAS Discov; 2021 Oct; 26(9):1107-1124. PubMed ID: 34111999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Patient-Derived Ovarian Cancer Models.
    Maru Y; Hippo Y
    Cells; 2019 May; 8(5):. PubMed ID: 31130643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
    Burkhart RA; Baker LA; Tiriac H
    Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Organoid-Based Preclinical Model of Human Gastric Cancer.
    Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
    Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
    Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.